Clue gets FDA clearance to launch a digital contraceptive Clue, an early pioneer in the femtech category with a well-regarded period-tracking app that’s used by around 13 million people, is getting ready to launch a digital contraceptive which will offer users a statistical prediction of ovulation as a birth control tool. A US launch of Clue Birth Control is slated for “this year”. The team won’t be more specific on the date yet. Pricing will be “premium” — but they’re also keeping the exact cost under wraps for now. The Berlin-based company is today announcing that they’ve gained FDA clearance for the forthcoming product, clearing the way for a US launch in 2021.